MED12 and prostate carcinoma: Subsequently, we analyzed MED12 protein expression in a panel of prostate cancer cell lines (AR-positive: LNCaP, 22Rv1, VCaP, and DuCaP; AR-negative: DU145 and PC3) and in 1 benign prostatic hyperplasia cell line (BPH1) (Fig. 1B).